Get started
Author

André van der Westhuizen

Observed names: A Van der Westhuizen, A van der Westhuizen, A. Van Der Westhuizen, A. Van der Westhuizen, A. van der Westhuizen, Andre Van Der Westhuizen, Andre Van Der Westhuizen (21130841), Andre Van der Westhuizen, Andre Westhuizen, Andre van der Westhuizen
Observed institutions: Griffith University, Institut Jules Bordet, Hunter Medical Research Institute, Breast Cancer Trials, Lake Macquarie Private Hospital, Calvary Mater Newcastle Hospital, International Breast Cancer Study Group, University of Portsmouth, University of Newcastle Australia, Macquarie University
ORCID: 0000-0002-2901-5252
Observed ORCID: 0000-0002-2901-5252
OpenAlex ID: A5078694638
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 522
PDF
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
2022 · Jeffrey S. Weber, Dirk Schadendorf, et al. · Journal of Clinical Oncology · 184
PDF
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
2017 · Marco Colleoni, Weixiu Luo, et al. · The Lancet Oncology · 122
Metastatic melanoma treatment: Combining old and new therapies
2015 · Ryan J. Davey, Andre van der Westhuizen, et al. · Critical Reviews in Oncology/Hematology · 91
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
2021 · Timothy A. Yap, Maria Vieito, et al. · Clinical Cancer Research · 85
PDF
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
2020 · Prachi Bhave, Lalit Pallan, et al. · British Journal of Cancer · 66
PDF
Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial
2022 · Jessica S. Crystal, John F. Thompson, et al. · JAMA Surgery · 55
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
2019 · Johanna C. Bendell, Tamara Sauri, et al. · The Oncologist · 49
PDF
Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities
2014 · C. Gedye, A. van der Westhuizen, et al. · Internal Medicine Journal · 41
PDF
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
2020 · Karin Ribi, Weixiu Luo, et al. · Breast Cancer Research and Treatment · 39
Targeting DNA Repair in Ovarian Cancer Treatment Resistance
2020 · M.W. Wong-Brown, A. van der Westhuizen, et al. · Clinical Oncology · 36
Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles
2019 · Moira Graves, Giovana CelliMarchett, et al. · Frontiers in Medicine · 24
PDF
Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
2022 · Michelle W. Wong-Brown, Andre van der Westhuizen, et al. · BMC Cancer · 21
PDF
Curative Strategies for Liver Metastases from Colorectal Cancer: A Review
2012 · Nicholas Zdenkowski, Stanley Chen, et al. · The Oncologist · 21
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
2020 · Vishal Navani, Moira C. Graves, et al. · British Journal of Clinical Pharmacology · 20
Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
2018 · Timothy Budden, Andre van der Westhuizen, et al. · BMC Cancer · 18
PDF
Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).
2017 · Johanna C. Bendell, Tamara Sauri, et al. · Journal of Clinical Oncology · 15
Teaching and learning in higher education: disciplinary approaches to educational enquiry
2015 · André van der Westhuizen · Innovations in Education and Teaching International · 14
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma
2025 · R.V. Rawson, N.G. Maher, et al. · Annals of Oncology · 11
PDF
Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
2022 · Andre van der Westhuizen, Megan Lyle, et al. · Cancer Research Communications · 11
Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
2021 · Vishal Navani, Moira C. Graves, et al. · Pharmacology Research & Perspectives · 9
PDF
Business as unusual: medical oncology services adapt and deliver during COVID ‐19
2021 · Avraham Travers, Kim Adler, et al. · Internal Medicine Journal · 7
Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis.
2020 · Prachi Bhave, Lalit Pallan, et al. · Journal of Clinical Oncology · 7
Impending infliximab access crisis: a case of steroid‐refractory, relapsing immunotherapy‐induced colitis responsive to infliximab
2020 · Elizabeth A. Connolly, Tim Walker, et al. · Internal Medicine Journal · 6
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)
2022 · Fiona Day, Swetha Sridharan, et al. · BMC Cancer · 5
PDF
Works count: 57
Citation count: 1,505
H-index: 16
I10-index: 20
Year
Topic
Type